This is an observational study that requires participants to undergo a variety of exams (such as cognitive assessments, MRIs, PET scans, and lumbar punctures) over the course of five years. Approximately 2,000 participants will be enrolled at 59 sites throughout the United States and Canada, including participants who may have previously been enrolled in ADNI2. Participants will represent three cohorts: individuals who are cognitively normal, those with mild cognitive impairment, and those who have mild Alzheimer’s disease.
What is the purpose of the ADNI-3 Study?
ADNI-3 continues the previous ADNI-1, ADNI-GO, and ADNI-2 collaborative efforts to determine the relationships between clinical, cognitive, imaging, genetic and biomarker characteristics of the entire spectrum of Alzheimer’s disease. ADNI-3 will continue to discover, optimize, standardize and validate clinical trial measures and biomarkers used in Alzheimer’s research. The data collected in this trial, along with previous ADNI studies, play a central role in improving the design of current and future Alzheimer’s disease treatment trials.
Men and women ages 55 to 90 years old with no memory impairment, a diagnosis of mild cognitive impairment, or a diagnosis of mild Alzheimer’s disease may be eligible.
If you are interested in learning more about the ADNI-3 study, please call (401) 455-6402 or send an e-mail email@example.com. Ask about the “ADNI-3 Trial.”